Novartis Boosted By Alcon, Generic Sales And Gilenya Launch in Second Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis lifted by strong sales of recently launched products in the second quarter, and by strong growth in its Alcon, generics and consumer health divisions.